|1.||Newman, Frances K: 3 articles (03/2007 - 04/2003)|
|2.||Yan, Lihan: 3 articles (03/2007 - 04/2003)|
|3.||Meseda, Clement A: 2 articles (10/2007 - 12/2005)|
|4.||He, Yong: 2 articles (10/2007 - 12/2005)|
|5.||Merchlinsky, Michael: 2 articles (10/2007 - 12/2005)|
|6.||Blevins, Tamara P: 2 articles (07/2003 - 04/2003)|
|7.||Belshe, Robert B: 2 articles (07/2003 - 04/2003)|
|8.||Frey, Sharon E: 2 articles (07/2003 - 04/2003)|
|9.||Poland, Gregory A: 1 article (09/2014)|
|10.||Kennedy, Richard B: 1 article (09/2014)|
08/01/2007 - "However, the currently licensed Dryvax vaccine, despite its documented efficacy in eradicating smallpox, is not optimal for the vaccination of contemporary populations with large numbers of individuals with immunodeficiencies because of severe adverse effects that can occur in such individuals. "
11/15/2003 - "These data show that immunological memory to DryVax vaccine is long-lived and may contribute to protection against smallpox."
09/01/2014 - "We previously reported HLA allelic associations with vaccinia virus (VACV)-induced adaptive immune responses in a cohort of healthy individuals (n = 1,071 subjects) after a single dose of the licensed smallpox (Dryvax) vaccine. "
06/01/2014 - "Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000."
01/24/2008 - "The potential use of smallpox as an agent of bioterrorism has renewed interest in the development of a modern vaccine capable of replacing the standard Dryvax vaccine. "
09/27/2005 - "We have analyzed by ex vivo ELISPOT the anti-vaccinia cytotoxic T lymphocyte responses of peripheral blood mononuclear cells from humans vaccinated with Dryvax vaccine. "
07/01/2003 - "The assessment of immunogenicity of a diluted vaccinia vaccine for possible widespread use of a diluted vaccine in the event of a bioterrorist attack prompted us to focus on the development of a sensitive and specific plaque reduction neutralization (PRN) assay to assess the antibody response of volunteers to a vaccinia (Dryvax) vaccine. "
04/15/2003 - "At refrigerator temperature, the decrease in vaccinia-vaccine titer during the first year was not significantly different between the undiluted Dryvax vaccine and either of the 2 diluted forms of Dryvax vaccine, with any of the 3 diluents."
07/01/2003 - "Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine."
03/15/2007 - "Eleven vaccine-dose groups, each with 30 vaccinia-naive subjects, were given diluted Dryvax vaccine or 1 of 2 lots of Sanofi Pasteur smallpox vaccine and were evaluated for vaccination success rates, morbidity, and immune responses. "
11/01/2007 - "We found that ex vivo-cultured tonsillar tissue supports productive infection by the New York City Board of Health strain, the VACV strain of the Dryvax vaccine. "
10/01/2007 - "Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity."
|4.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)